CD19 and acute lymphoblastic leukemia: Since the first anti-CD19 CAR T-cell product was approved for the treatment of acute lymphoblastic leukemia (ALL) by the US Food and Drug Administration (FDA) in 2017, several more CAR T-cell products targeting CD19 and other antigens have been developed [3, 4].